What the SURMOUNT trials really tell us about tirzepatide and weight loss

The myth: the SURMOUNT trials involved tens of thousands of people and prove tirzepatide works for everyone

This is the version that circulates most on social media, and it is wrong on both counts. SURMOUNT-1 (the flagship trial) randomised 2,539 participants over 72 weeks. The broader tirzepatide clinical programme, including the diabetes-focused SURPASS trials, reaches beyond 10,000 participants in total, which is where larger numbers sometimes originate. Conflating the two is an honest mistake, but it matters: the weight-management evidence base is robust and well-powered, yet it is not the scale sometimes claimed.

More importantly, SURMOUNT-1 enrolled adults with a BMI of 30 or above (or 27 with a weight-related condition) who did not have type 2 diabetes, and all participants received structured dietary support and activity counselling alongside the medicine. The results (published in the New England Journal of Medicine) cannot be separated from that support framework. Tirzepatide as a standalone fix, taken without any lifestyle changes, was not what was tested. The medicine worked inside a structured programme, and that is the context clinicians apply when they review a patient today.

The 20–21% average weight reduction at 15 mg is genuinely striking. But it is a mean across a distribution, some participants lost more, many lost less, and a small number lost very little. That variability is part of why clinical assessment before prescribing matters, and why NICE guidance specifies reviewing continuation if weight loss falls below 5% after six months at the highest tolerated dose. The trials do not prove tirzepatide works for everyone; they show it produces meaningful average weight loss in a defined population under monitored conditions.

What SURMOUNT-1 through SURMOUNT-4 each contributed

The programme was not a single experiment run four times. Each trial answered a different question. SURMOUNT-1 established the core efficacy and safety signal in adults with obesity without diabetes, the foundational data the regulators used. SURMOUNT-2 replicated the approach in adults with type 2 diabetes alongside obesity, where the baseline metabolic picture differs substantially and weight loss is typically harder to achieve; results remained clinically meaningful. SURMOUNT-3 tested an intensive lead-in: participants first completed a very low-calorie diet phase before being randomised to tirzepatide or placebo, exploring what happens when the medicine follows an established deficit. SURMOUNT-4 addressed a question that matters enormously to anyone considering long-term treatment, what happens when you stop? Participants who had lost weight on tirzepatide were switched to placebo; weight regain followed, underscoring that the medicine addresses a biological condition that does not resolve once a course ends.

Taken together, the four trials build a coherent picture: tirzepatide produces substantial average weight loss across different patient groups, the effect requires ongoing treatment to maintain, and individual outcomes vary. For a thorough look at the percentage figures across the programme, our analysis of weight-loss percentages across the SURMOUNT trials sets them out alongside the trial design caveats.

SURMOUNT-5: the head-to-head comparison with semaglutide

SURMOUNT-5 is the trial that generated the most clinical discussion in 2025. It was an open-label, 72-week study that enrolled 751 adults with obesity and no diabetes, randomising them to either tirzepatide (titrated to the highest tolerated dose up to 15 mg) or semaglutide 2.4 mg weekly. Published in the New England Journal of Medicine in 2025, it found that tirzepatide produced greater average weight reduction than semaglutide at the doses studied. NICE's committee, in its appraisal of tirzepatide (TA1026), noted that indirect comparisons also favour tirzepatide, and SURMOUNT-5 added direct evidence to that picture.

The open-label design is worth understanding: both participants and investigators knew which medicine was being taken, which can influence behaviour and reporting. The comparison was also at 2.4 mg for semaglutide (Wegovy's standard maintenance dose at the time) rather than the higher 7.2 mg dose approved by the MHRA in early 2026, which narrows the gap in later data. Neither trial tells you which medicine is right for a specific person. That is a clinical judgement that depends on medical history, other medicines, tolerability and individual preference, the kind of assessment a prescriber makes at consultation, not a ranking you can read off a chart.

From trial data to a prescription: how the evidence is used in practice

The SURMOUNT results underpinned the UK licensing of tirzepatide as Mounjaro for weight management, and NICE's positive recommendation (TA1026, December 2024) extended access through NHS England in phased cohorts. Privately, a tirzepatide prescription requires the same clinical assessment: a prescriber reviews your BMI, medical history, current medicines and weight-related conditions before deciding whether it is appropriate. There is no clinical shortcut that the trial data creates, if anything, the trials reinforce why that review matters.

For cost context, the Mounjaro pricing page sets out what UK private treatment involves. One thing the trials tell us clearly is that this is a medicine taken over months, not weeks, the 72-week duration in SURMOUNT-1 was chosen deliberately, and the SURMOUNT-4 withdrawal data shows why duration matters. If you are considering treatment based on the trial evidence, the practical next step is a consultation with a prescriber who can apply that evidence to your specific situation. If you do go ahead with a private prescription through a regulated pharmacy, the medicine itself (a pre-filled KwikPen, tracked by DPD, in plain unbranded packaging) is the same licensed Mounjaro supplied through the UK's authorised supply chain. The trial data and the pen in your fridge are connected by a chain of regulation that matters far more than the price tag.

Our clinical team reviews every consultation personally. If you have questions about the trial evidence before starting, the FAQs cover the most common ones, or you can get in touch directly. When you are ready, check your eligibility with a free consultation.